BR112014015991A2 - composto, composição farmacêutica e processo de preparação de um composto - Google Patents

composto, composição farmacêutica e processo de preparação de um composto

Info

Publication number
BR112014015991A2
BR112014015991A2 BR112014015991A BR112014015991A BR112014015991A2 BR 112014015991 A2 BR112014015991 A2 BR 112014015991A2 BR 112014015991 A BR112014015991 A BR 112014015991A BR 112014015991 A BR112014015991 A BR 112014015991A BR 112014015991 A2 BR112014015991 A2 BR 112014015991A2
Authority
BR
Brazil
Prior art keywords
compound
preparing
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
BR112014015991A
Other languages
English (en)
Other versions
BR112014015991A8 (pt
BR112014015991B1 (pt
Inventor
Deprez Benoit
Bougeret Cécile
Carniato Dennis
Briand Jean-François
Jaillardon Karine
Gutmann Mathieu
Busnel Olivier
Original Assignee
Marc Henry Pitty
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marc Henry Pitty filed Critical Marc Henry Pitty
Publication of BR112014015991A2 publication Critical patent/BR112014015991A2/pt
Publication of BR112014015991A8 publication Critical patent/BR112014015991A8/pt
Publication of BR112014015991B1 publication Critical patent/BR112014015991B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112014015991-2A 2011-12-30 2012-12-28 Composto, uso do composto, composição farmacêutica, uso da composição farmacêutica e método de preparação de um composto BR112014015991B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1162586A FR2985256B1 (fr) 2011-12-30 2011-12-30 Derives piperazinyles pour le traitement de cancers
FR1162586 2011-12-30
PCT/EP2012/077059 WO2013098393A1 (fr) 2011-12-30 2012-12-28 Derives piperazinyles pour le traitement de cancers

Publications (3)

Publication Number Publication Date
BR112014015991A2 true BR112014015991A2 (pt) 2017-06-13
BR112014015991A8 BR112014015991A8 (pt) 2017-07-04
BR112014015991B1 BR112014015991B1 (pt) 2022-11-16

Family

ID=47470025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014015991-2A BR112014015991B1 (pt) 2011-12-30 2012-12-28 Composto, uso do composto, composição farmacêutica, uso da composição farmacêutica e método de preparação de um composto

Country Status (18)

Country Link
US (1) US9321778B2 (pt)
EP (1) EP2797898B9 (pt)
JP (1) JP6105625B2 (pt)
KR (1) KR102086732B1 (pt)
CN (1) CN104053648B (pt)
AU (1) AU2012360815B2 (pt)
BR (1) BR112014015991B1 (pt)
CA (1) CA2859721C (pt)
ES (1) ES2606289T3 (pt)
FR (1) FR2985256B1 (pt)
HK (1) HK1202118A1 (pt)
HU (1) HUE030951T2 (pt)
IL (1) IL233414A (pt)
PL (1) PL2797898T3 (pt)
RU (1) RU2629115C2 (pt)
SG (1) SG11201403727YA (pt)
WO (1) WO2013098393A1 (pt)
ZA (1) ZA201405068B (pt)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10358539A1 (de) * 2003-12-15 2005-07-07 Merck Patent Gmbh Carbonsäureamidderivate
US20060058296A1 (en) * 2003-12-24 2006-03-16 Scios, Inc. Treatment of osteolytic lesions associated with multiple myeloma by inhibition of p38 map kinase
CN101010315A (zh) * 2004-04-30 2007-08-01 拜耳制药公司 用于治疗癌症的取代的吡唑基脲衍生物
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
WO2008135786A1 (en) * 2007-05-04 2008-11-13 Astrazeneca Ab Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer
FR2932483A1 (fr) * 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
WO2010091164A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
WO2010133885A1 (en) * 2009-05-21 2010-11-25 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
ES2704862T3 (es) * 2010-07-16 2019-03-20 Agios Pharmaceuticals Inc Composiciones terapéuticamente activas y su método de uso
US20130071328A1 (en) 2011-03-22 2013-03-21 University Of Southern California Propynoic Acid Carbamoyl Methyl-Amides and Pharmaceutical Compositions and Methods Based Thereon

Also Published As

Publication number Publication date
EP2797898B9 (fr) 2021-05-26
CA2859721A1 (fr) 2013-07-04
HK1202118A1 (en) 2015-09-18
ZA201405068B (en) 2015-11-25
WO2013098393A1 (fr) 2013-07-04
JP2015505308A (ja) 2015-02-19
AU2012360815A1 (en) 2014-07-31
BR112014015991A8 (pt) 2017-07-04
AU2012360815B2 (en) 2017-02-02
ES2606289T3 (es) 2017-03-23
RU2014131001A (ru) 2016-02-20
IL233414A (en) 2015-11-30
EP2797898B1 (fr) 2016-09-14
IL233414A0 (en) 2014-08-31
FR2985256A1 (fr) 2013-07-05
PL2797898T3 (pl) 2017-03-31
EP2797898A1 (fr) 2014-11-05
BR112014015991B1 (pt) 2022-11-16
JP6105625B2 (ja) 2017-03-29
FR2985256B1 (fr) 2016-03-04
KR102086732B1 (ko) 2020-03-09
US20140356360A1 (en) 2014-12-04
SG11201403727YA (en) 2014-09-26
RU2629115C2 (ru) 2017-08-24
CN104053648A (zh) 2014-09-17
NZ627149A (en) 2015-08-28
US9321778B2 (en) 2016-04-26
HUE030951T2 (en) 2017-06-28
CN104053648B (zh) 2016-09-28
KR20140117456A (ko) 2014-10-07
CA2859721C (fr) 2020-01-07

Similar Documents

Publication Publication Date Title
BR112014010197A2 (pt) composto, composição farmacêutica, método de tratamento de um distúrbio
BR112014007645A2 (pt) composto heterocíclico, métodos para a preparação de um composto heterocíclico, e, composição farmacêutica
BR112013008008A2 (pt) composto, composição farmacêutica e processo para preparar um composto
BR112014012878A2 (pt) composto, método de tratamento de emese, composição farmacêutica, método de fabricação, método sintético e método para estabilização de um composto
BR112014008196A2 (pt) processo para a preparação de um composto
BR112014003798A2 (pt) método para fabricar um composto, e, composto
BR112014012414A2 (pt) processo para a preparação de 5-flúor-1h-pirazolopiridinas substituídas
BR112014003111A2 (pt) “processo para preparar um composto de 1h-pirazol-5- carbonilcloreto n-substituído e processo para preparar um composto de sulfimina”
BR112014012243A2 (pt) processo de preparação de compostos
BRPI1012018A2 (pt) processo para preparar um composto
BR112015003101A2 (pt) processo para a preparação de um composto.
BR112013018945A2 (pt) processo para a preparação de 4-amino-5-fluoro-3-halo-6-(substituído)picolinatos.
BR112014010479A2 (pt) composto, método para preparar um composto, método para a preparação de icotinib a partir de um composto e método para a preparação de cloridrato de icotinib a partir de um composto
BRPI0914674A2 (pt) processo para preparação de um pó
BR112014013354A2 (pt) processo para a preparação de um polímero, composição, composto, e, formulação
BR112014001769A2 (pt) processo para a preparação de 1,4-ciclo-hexanodimetanol
BR112014014291A2 (pt) processo para preparar um catalisador
BR112014003336A2 (pt) processo para a preparação de complexos de 68ga
BR112014009437A2 (pt) processo para preparar um composto, composto e uso de um composto
BR112014010327A2 (pt) processo para a preparação de compostos
BR112014004588A2 (pt) processo de preparação da l-metionina
BR112012021379A2 (pt) processo para a preparação de um alqueno
BR112012003775A2 (pt) processo para a preparação de um composto, composto e composição
BR112014015512A2 (pt) processo para a preparação de um composto
BR112014004437A2 (pt) composto, uso de um composto, composição farmacêutica, preparação farmacêutica, processo para preparação de um composto, e intermediário.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/12/2012, OBSERVADAS AS CONDICOES LEGAIS